Alvotech kynnir jákvæða niðurstöðu rannsóknar á sjúklingum sem sýnir sömu klínísku virkni líftæknilyfjahliðstæðunnar AVT05 og Simponi® (golimumab)
April 24, 2024 04:00 ET
|
Alvotech
Meginendapunktur rannsóknarinnar var uppfylltur, þegar borin var saman klínísk virkni, öryggi og ónæmingarverkun AVT05 og Simponi (golimumab) í sjúklingum með meðallagi alvarlega eða alvarlega...
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
April 24, 2024 04:00 ET
|
Alvotech
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid...
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
April 24, 2024 04:00 ET
|
Alvotech
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid...
Tower Semiconductor Announces First Quarter 2024 Financial Results and Conference Call
April 24, 2024 03:00 ET
|
Tower Semiconductor
MIGDAL HAEMEK, Israel – April 24, 2024 – Tower Semiconductor (NASDAQ/ TASE: TSEM), the leading foundry of high-value analog semiconductor solutions, will issue its first quarter 2024 earnings release...
Futu Announces the Number of Its Clients in Malaysia Has Surpassed 100,000
April 24, 2024 02:30 ET
|
Futu Holdings Limited
HONG KONG, April 24, 2024 (GLOBE NEWSWIRE) -- Futu Holdings Limited (“Futu” or the “Company”) (Nasdaq: FUTU), a leading tech-driven online brokerage and wealth management platform, today announced...
Pharming Group to report first quarter 2024 financial results on May 8
April 24, 2024 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial...
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
April 24, 2024 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including...
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
April 24, 2024 01:00 ET
|
Pharming Group N.V.
Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the...
Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2023
April 23, 2024 21:59 ET
|
Xunlei Limited
SHENZHEN, China, April 24, 2024 (GLOBE NEWSWIRE) -- Xunlei Limited (“Xunlei” or the “Company”) (NASDAQ: XNET), a leading technology company providing distributed cloud services in China, today...
Vertex, Inc. Announces Pricing of Upsized $300 Million Convertible Senior Notes Offering
April 23, 2024 21:53 ET
|
Vertex Inc.
KING OF PRUSSIA, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex”), a leading global provider of indirect tax solutions, today announced the pricing of $300 million...